Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.

IF 2.8 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-06-26 DOI:10.1097/CCO.0000000000000967

Carmine Valenza, Dario Trapani, Giuseppe Curigliano

{"title":"Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.","authors":"Carmine Valenza, Dario Trapani, Giuseppe Curigliano","doi":"10.1097/CCO.0000000000000967","DOIUrl":null,"url":null,"abstract":"Purpose of review: Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to immune-checkpoint inhibitors (ICIs). In this review, we aimed to summarize the most important preclinical evidences of IBC immune-vulnerability and the first data from clinical trials evaluating ICIs in IBC.Recent findings: IBC is characterized by a preexisting active immune TME suppressed by mechanisms of immune-escape, including inhibitory immune-checkpoints, whose expression is higher than in non-IBC. Clinical trials evaluating ICIs in patients with IBC are burdened by slow accrual and low enrollment.Summary: Because of the limited data from clinical trials, no conclusions about the activity of ICIs in IBC can be drawn. Ongoing clinical trials are assessing many promising ICI-based combination approaches. An enhanced multicenter collaboration to evaluate ICIs in patients with this aggressive form of disease and to improve clinical outcomes is required.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"507-512"},"PeriodicalIF":2.8000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000000967","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to immune-checkpoint inhibitors (ICIs). In this review, we aimed to summarize the most important preclinical evidences of IBC immune-vulnerability and the first data from clinical trials evaluating ICIs in IBC.

Recent findings: IBC is characterized by a preexisting active immune TME suppressed by mechanisms of immune-escape, including inhibitory immune-checkpoints, whose expression is higher than in non-IBC. Clinical trials evaluating ICIs in patients with IBC are burdened by slow accrual and low enrollment.

Summary: Because of the limited data from clinical trials, no conclusions about the activity of ICIs in IBC can be drawn. Ongoing clinical trials are assessing many promising ICI-based combination approaches. An enhanced multicenter collaboration to evaluate ICIs in patients with this aggressive form of disease and to improve clinical outcomes is required.

查看原文本刊更多论文

炎症性乳腺癌症的免疫治疗：当前证据和未来展望。

综述目的：炎症性乳腺癌症（IBC）是临床上癌症最致命的表现类型。IBC的免疫肿瘤微环境（TME）以免疫逃避信号为特征，但表明其对免疫检查点抑制剂（ICIs）具有可操作的脆弱性。在这篇综述中，我们旨在总结IBC免疫脆弱性的最重要的临床前证据，以及评估IBC中ICIs的临床试验的第一批数据。最近的发现：IBC的特征是预先存在的活性免疫TME被免疫逃逸机制抑制，包括抑制性免疫检查点，其表达高于非IBC。评估IBC患者ICI的临床试验因缓慢的累积和低登记率而负担沉重。摘要：由于临床试验的数据有限，无法得出关于ICIs在IBC中的活性的结论。正在进行的临床试验正在评估许多有前景的基于ICI的联合方法。需要加强多中心合作来评估这种侵袭性疾病患者的ICIs并改善临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.